



7 February 2013

ABN 89 113 824 141

www.neurodiscoveryltd.com

The Manager
Company Announcements Office
ASX Limited
Level 6, 20 Bridge Street
SYDNEY NSW 2000

NeuroDiscovery Appoints Dr Roger Aston as Chairman

NeuroDiscovery is pleased to announce the proposed appointment of Dr Roger Aston as an Executive Chairman of the Company subject to shareholder approval of its acquisition of Enigma Therapeutics as announced on 7 February 2013.

Dr Roger Aston is currently the CEO of Pitney Pharmaceuticals Ltd, chairman of BioLife Ltd, director of Immuron Ltd, director of IDT Ltd, Director of Regeneus Ltd and Cynata Ltd. He holds a B.Sc. (Hons) and Ph.D. degrees at the University of Manchester (1975-1981) and worked previously at the Wellcome Foundation now Glaxo SmithKline. Since 1981 Mr Aston has worked with Peptech, Cambridge Antibody Technology, Cambridge Drug Discovery, QinetiQ, Clinuvel, pSiMedica, pSivida, Halcygen, Ascent Pharma Health and his last position was CEO of Mayne Pharma Group.

Yours faithfully

David McAuliffe
Executive Director

+61 8 9385 3552